Real-life evaluation of BioFire® BCID2 and Vitek® REVEALTM for Gram-negative bloodstream infections in critical care
4 affiliations
- 1Department of Microbiology and Hospital Hygiene, Nîmes University Hospital, Nîmes, France
- 2Division of Anesthesia and Critical Care, UR-UM103 IMAGINE, University of Montpellier, Pain and Emergency Medicine, Nîmes University Hospital, Nîmes, France
- 3Department of Biostatistics, Epidemiology, Public Health, and Innovation in Methodology (BESPIM), Nîmes University Hospital, Nîmes, France
- 4VBIC, INSERM U1047, University of Montpellier, Nîmes, France
Abstract
Timely management of sepsis relies on rapid diagnosis of bloodstream infections (BSIs), including early pathogen identification and antimicrobial susceptibility testing (AST). The Vitek® REVEALTM is an innovative rapid AST platform that detects volatile organic compounds emitted by Gram-negative bacilli (GNB) directly from positive blood cultures. This study assessed the analytical performance and clinical contribution of the BioFire® BCID2 molecular panel and the Vitek® REVEALTM system in the diagnosis of GNB-BSI among intensive care unit (ICU) patients. We analyzed the prospective phase of the BacteREVEAL study, conducted between March and October 2023 at Nîmes University Hospital. Results from BioFire® BCID2 and Vitek® REVEALTM were compared to standard-of-care methods, including MALDI-TOF identification and direct disk diffusion AST. Performance metrics for Vitek® REVEALTM were evaluated according to ISO 20776–2:2007 standards. Among 94 ICU patients with a first episode of GNB-BSI, 50 monomicrobial cases were included. Escherichia coli was the most frequently identified species (n = 30, 60%), followed by Pseudomonas aeruginosa (n = 7, 14%). BioFire® BCID2 provided accurate identification for all isolates. The innovative tools reduced median turnaround times for identification by 19.0 h and for AST by 14.9 h. The mean time to result for Vitek® REVEALTM was 5.7 h. Overall categorical agreement with standard AST was 97.7%, with 8 very major errors, 8 major errors, and 2 minor errors. These findings support the integration of BioFire® BCID2 and Vitek® REVEALTM into routine workflows to accelerate GNB-BSI diagnosis and improve sepsis management.
Related
- Application and evaluation of nanopore targeted sequencing in the detection of bacterial and fungal pathogens in leukemia bloodstream infections.
- Bacterial profile and antibiotic susceptibility of bloodstream infections among infants, children, and adolescents undergoing treatment for acute leukemia
- Enhanced detection of polymicrobial bloodstream infections with 16S rDNA PCR library amplicons and clinical relevance
- Burden of Intestinal Parasitic Infections and the Intensity of Helminth Infection Among Primary School Children in Sidama, Ethiopia: A Zero-Inflated Negative Binomial Analysis.
- Metagenomic next-generation sequencing improves pathogen detection in culture-negative infections: a diagnostic performance study
BibTeX
@article{benyahia2026reallife,
title = {{Real-life evaluation of BioFire® BCID2 and Vitek® REVEALTM for Gram-negative bloodstream infections in critical care}},
author = {Massinissa Benyahia and Claire Roger and Adeline Boutet-Dubois and Florian Salipante and Louis Oudiane and Matthieu Curtil Dit Galin and Rim Nsiri and Léo Brochon and Jean-Philippe Lavigne and Alix Pantel},
journal = {PLOS One},
year = {2026},
month = sep,
doi = {10.1371/journal.pone.0356199},
url = {https://doi.org/10.1371/journal.pone.0356199},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Real-life evaluation of BioFire® BCID2 and Vitek® REVEALTM for Gram-negative bloodstream infections in critical care
AU - Massinissa Benyahia
AU - Claire Roger
AU - Adeline Boutet-Dubois
AU - Florian Salipante
AU - Louis Oudiane
AU - Matthieu Curtil Dit Galin
AU - Rim Nsiri
AU - Léo Brochon
AU - Jean-Philippe Lavigne
AU - Alix Pantel
PY - 2026
DA - 2026/09/10
JO - PLOS One
DO - 10.1371/journal.pone.0356199
UR - https://doi.org/10.1371/journal.pone.0356199
AB - Timely management of sepsis relies on rapid diagnosis of bloodstream infections (BSIs), including early pathogen identification and antimicrobial susceptibility testing (AST). The Vitek® REVEALTM is an innovative rapid AST platform that detects volatile organic compounds emitted by Gram-negative bacilli (GNB) directly from positive blood cultures. This study assessed the analytical performance and clinical contribution of the BioFire® BCID2 molecular panel and the Vitek® REVEALTM system in the diagnosis of GNB-BSI among intensive care unit (ICU) patients. We analyzed the prospective phase of the BacteREVEAL study, conducted between March and October 2023 at Nîmes University Hospital. Results from BioFire® BCID2 and Vitek® REVEALTM were compared to standard-of-care methods, including MALDI-TOF identification and direct disk diffusion AST. Performance metrics for Vitek® REVEALTM were evaluated according to ISO 20776–2:2007 standards. Among 94 ICU patients with a first episode of GNB-BSI, 50 monomicrobial cases were included. Escherichia coli was the most frequently identified species (n = 30, 60%), followed by Pseudomonas aeruginosa (n = 7, 14%). BioFire® BCID2 provided accurate identification for all isolates. The innovative tools reduced median turnaround times for identification by 19.0 h and for AST by 14.9 h. The mean time to result for Vitek® REVEALTM was 5.7 h. Overall categorical agreement with standard AST was 97.7%, with 8 very major errors, 8 major errors, and 2 minor errors. These findings support the integration of BioFire® BCID2 and Vitek® REVEALTM into routine workflows to accelerate GNB-BSI diagnosis and improve sepsis management.
SN - 1932-6203
ER -